MacroPore Announces Japan Prospects, Withdraws Revenue Guidance
This article was originally published in The Gray Sheet
Executive Summary
MacroPore stands to gain up to $10 mil. in revenue over three years via minimum purchase agreements and royalties from Japanese distribution firm Senko Medical Trading Co., assuming MAST Biosurgery AG does not exercise its option to acquire those rights
You may also be interested in...
Regenerative Cell Technology Research Constitutes Heart Of MacroPore R&D
MacroPore Biosurgery is focusing its R&D dollars on regenerative cell therapy as its biomaterials business struggles to meet expectations
Regenerative Cell Technology Research Constitutes Heart Of MacroPore R&D
MacroPore Biosurgery is focusing its R&D dollars on regenerative cell therapy as its biomaterials business struggles to meet expectations
Cardiac Stem Cell Alliances Include Large Firms; MacroPore “Grows” It Alone
MacroPore Biosurgery insists it will pursue solo development of stem cell therapy for myocardial infarction, even though competitors are increasingly aligning with large cardiovascular device firms